Otsuka starts ulcerative colitis Phase III

Otsuka (Tokyo, Japan) began two Phase III trials of its OPC-6535, a phosphodiesterase 4 (PDE 4) inhibitor to treat ulcerative colitis. The trials will enroll 750 patients in the U.S., Canada and Austr...